Disease overview

Alterations

104

Molecular (A)

100

Clinical (B–E)

Direct drugs

168

Via biomarker

125

Natural agents

Natural products

Merged ranked

292

With trial/literature evidence

Sources: Open Targets, ClinicalTrials.gov, ChEMBL, DGIdb, PubMed MeSH, PubMed Literature, PubMed NP, ClinicalTrials.gov NP · Pipeline phase 7 · Updated 2026-07-05

Remission & chronicity

Spontaneous remission

MASH (formerly NASH) with fibrosis progresses to cirrhosis in ~20% over 10 years on standard care (which until 2024 was lifestyle modification only); fibrosis regression occurs spontaneously in ~25% over 5 years with sustained weight loss

Best-intervention remission

Resmetirom (Rezdiffra) — first FDA-approved pharmacotherapy for MASH (March 2024): 26-30% histological resolution at 52 weeks vs 10% placebo; bariatric surgery achieves MASH resolution in 85% and fibrosis regression in 35% at 5 years; >7-10% weight loss resolves MASH in ~50%

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — first drug only just approved in 2024 after decades of failed trials; practice still dominated by lifestyle advice alone

Primary barrier

biological (historical) + access (current)

Barrier detail: Until March 2024, there was literally no approved pharmacotherapy for MASH despite it being a leading cause of cirrhosis and liver transplant; the field repeatedly failed Phase 3 (obeticholic acid, elafibranor, selonsertib, cenicriviroc — all negative); resmetirom is a genuine breakthrough but access and prescribing uptake are still ramping up

Last SoC change: March 2024 — resmetirom (Rezdiffra) FDA approved — the first pharmacotherapy for MASH; prior standard was weight loss and lifestyle only since MASH was described in 1980

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0007027 · MESH: D065626 · UMLS_CUI: C2711227

Alterations

104 total · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
ACACA acetyl-CoA carboxylase alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADORA2A adenosine A2a receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADORA2B adenosine A2b receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AGTR1 angiotensin II receptor type 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CASP1 caspase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCR2 C-C motif chemokine receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCR5 C-C motif chemokine receptor 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CNR1 cannabinoid receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4 cytochrome c oxidase associated subunit FA4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
COXFA4L2 cytochrome c oxidase hypoxia associated subunit FA4L2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change in energy intake	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DPP4 dipeptidyl peptidase 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Description of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
ESR1 estrogen receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FGFR4 fibroblast growth factor receptor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GCGR glucagon receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GLP1R glucagon like peptide 1 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GPD2 glycerol-3-phosphate dehydrogenase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Inflammatory marker	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
KLB klotho beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LEPR leptin receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LEPROT leptin receptor overlapping transcript	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP3K5 mitogen-activated protein kinase kinase kinase 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND1 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND2 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND3 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND4 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND4L mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 4L	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND5 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MT-ND6 mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Metabolic profile	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
NDUFA1 NADH:ubiquinone oxidoreductase subunit A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA10 NADH:ubiquinone oxidoreductase subunit A10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA11 NADH:ubiquinone oxidoreductase subunit A11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA12 NADH:ubiquinone oxidoreductase subunit A12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA13 NADH:ubiquinone oxidoreductase subunit A13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA2 NADH:ubiquinone oxidoreductase subunit A2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA3 NADH:ubiquinone oxidoreductase subunit A3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA5 NADH:ubiquinone oxidoreductase subunit A5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA6 NADH:ubiquinone oxidoreductase subunit A6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA7 NADH:ubiquinone oxidoreductase subunit A7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA8 NADH:ubiquinone oxidoreductase subunit A8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFA9 NADH:ubiquinone oxidoreductase subunit A9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAB1 NADH:ubiquinone oxidoreductase subunit AB1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF1 NADH:ubiquinone oxidoreductase complex assembly factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF2 NADH:ubiquinone oxidoreductase complex assembly factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF3 NADH:ubiquinone oxidoreductase complex assembly factor 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFAF4 NADH:ubiquinone oxidoreductase complex assembly factor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB1 NADH:ubiquinone oxidoreductase subunit B1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB10 NADH:ubiquinone oxidoreductase subunit B10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB11 NADH:ubiquinone oxidoreductase subunit B11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB2 NADH:ubiquinone oxidoreductase subunit B2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB3 NADH:ubiquinone oxidoreductase subunit B3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB4 NADH:ubiquinone oxidoreductase subunit B4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB5 NADH:ubiquinone oxidoreductase subunit B5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB6 NADH:ubiquinone oxidoreductase subunit B6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB7 NADH:ubiquinone oxidoreductase subunit B7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB8 NADH:ubiquinone oxidoreductase subunit B8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFB9 NADH:ubiquinone oxidoreductase subunit B9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFC1 NADH:ubiquinone oxidoreductase subunit C1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFC2 NADH:ubiquinone oxidoreductase subunit C2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS1 NADH:ubiquinone oxidoreductase core subunit S1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS2 NADH:ubiquinone oxidoreductase core subunit S2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS3 NADH:ubiquinone oxidoreductase core subunit S3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS4 NADH:ubiquinone oxidoreductase subunit S4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS5 NADH:ubiquinone oxidoreductase subunit S5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS6 NADH:ubiquinone oxidoreductase subunit S6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS7 NADH:ubiquinone oxidoreductase core subunit S7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFS8 NADH:ubiquinone oxidoreductase core subunit S8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV1 NADH:ubiquinone oxidoreductase core subunit V1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV2 NADH:ubiquinone oxidoreductase core subunit V2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NDUFV3 NADH:ubiquinone oxidoreductase subunit V3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NR1H4 nuclear receptor subfamily 1 group H member 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE10A phosphodiesterase 10A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE1A phosphodiesterase 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE1B phosphodiesterase 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE1C phosphodiesterase 1C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE2A phosphodiesterase 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE3A phosphodiesterase 3A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE3B phosphodiesterase 3B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4A phosphodiesterase 4A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4B phosphodiesterase 4B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4C phosphodiesterase 4C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4D phosphodiesterase 4D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE5A phosphodiesterase 5A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE6A phosphodiesterase 6A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE6B phosphodiesterase 6B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE6C phosphodiesterase 6C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE6D phosphodiesterase 6D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE6G phosphodiesterase 6G	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE6H phosphodiesterase 6H	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE7A phosphodiesterase 7A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE7B phosphodiesterase 7B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE8A phosphodiesterase 8A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE8B phosphodiesterase 8B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE9A phosphodiesterase 9A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PNPLA3 patatin like domain 3, 1-acylglycerol-3-phosphate O-acyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPARA peroxisome proliferator activated receptor alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPARD peroxisome proliferator activated receptor delta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PPARG peroxisome proliferator activated receptor gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
SLC5A2 solute carrier family 5 member 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
THRB thyroid hormone receptor beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
VDR vitamin D receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
RESMETIROM	Small molecule	Approved	Strong	105	4 trials 7 Cochrane 9 Meta-analysis 9 Trial pubs 9 RCT View evidence Registry trials NCT07335601 — Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH (RECRUITING) PHASE2 NCT07680478 — Nutrition Intervention Combined With Resmetirom for MASH (NOT_YET_RECRUITING) PHASE4 NCT07249788 — Resmiterom Efficacy & Safety in Patients With MASH (RECRUITING) PHASE4 NCT07541469 — Rezdiffra Pregnancy and Lactation Registry (RECRUITING) Published literature Cochrane review The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026) Cochrane review Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials (Med (New York, N.Y.), 2026) Cochrane review Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH) (Diabetes, obesity & metabolism, 2026) Cochrane review Clinical Assessment of Common Medications for Nonalcoholic Fatty Liver Disease: A Systematic Review and Bayesian Network Meta-Analysis (Journal of evidence-based medicine, 2025) Cochrane review Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials (Journal of basic and clinical physiology and pharmacology, 2025) Meta-analysis Development of a cross-species model to predict clinical outcomes based on efficacy in mouse models of non-alcoholic fatty liver disease (Clinics and research in hepatology and gastroenterology, 2025) Meta-analysis Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction-associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta-analysis (Diabetes, obesity & metabolism, 2025) Meta-analysis A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis (Liver international : official journal of the International Association for the Study of the Liver, 2025) Systematic review Efficacy and safety of resmetirom for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis (European journal of gastroenterology & hepatology, 2025) Systematic review Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2024) Clinical trial publication Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis (Hepatology communications, 2026) Clinical trial publication Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial (Alimentary pharmacology & therapeutics, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
BICALUTAMIDE	Small molecule	Approved	Strong	100	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ADENOSINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALITRETINOIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMINOPHYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANGIOTENSIN II Repurposing	Small molecule	Approved	Strong	95	2 Trial pubs 2 RCT View evidence Published literature Clinical trial publication Randomized placebo-controlled trial of losartan for pediatric NAFLD (Hepatology (Baltimore, Md.), 2022) Clinical trial publication A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis (PloS one, 2017) CT.gov search · Cochrane · PubMed	DGIdb	—
ANGIOTENSIN II ACETATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ASCORBIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing	Small molecule	Approved	Strong	95	1 Cochrane 1 Meta-analysis 13 Trial pubs 12 RCT View evidence Published literature Cochrane review Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (The Cochrane database of systematic reviews, 2013) Clinical trial publication Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial (PloS one, 2025) Clinical trial publication Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial (Hepatology international, 2023) Clinical trial publication Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial (European heart journal, 2022) Clinical trial publication Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role? (Current vascular pharmacology, 2021) Clinical trial publication CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients (Liver international : official journal of the International Association for the Study of the Liver, 2019) CT.gov search · Cochrane · PubMed	DGIdb	—
ATORVASTATIN CALCIUM TRIHYDRATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
AZILSARTAN KAMEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
AZILSARTAN MEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE CITRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CANNABIDIOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPTOPRIL Repurposing	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CYCLOSPORINE Repurposing	Small molecule	Approved	Strong	95	8 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DEFIBROTIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE Repurposing	Small molecule	Approved	Strong	95	15 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DIAZEPAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DISULFIRAM Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs View evidence Published literature Clinical trial publication Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism (Nature communications, 2022) CT.gov search · Cochrane · PubMed	DGIdb	—
DRONABINOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPROSARTAN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
EPROSARTAN MESYLATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLAVONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GENISTEIN Repurposing	Small molecule	Approved	Strong	95	1 Cochrane 2 Meta-analysis 1 Trial pubs 1 RCT View evidence Published literature Cochrane review Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis (Frontiers in immunology, 2022) Meta-analysis Therapeutic potential of traditional Chinese medicine in the prevention and treatment of digestive inflammatory cancer transformation: Portulaca oleracea L. as a promising drug (Journal of ethnopharmacology, 2024) Systematic review Polyphenol Intervention Ameliorates Non-Alcoholic Fatty Liver Disease: An Updated Comprehensive Systematic Review (Nutrients, 2024) Clinical trial publication Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial (Clinical nutrition (Edinburgh, Scotland), 2018) CT.gov search · Cochrane · PubMed	DGIdb	—
GLATIRAMER Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROCHLOROTHIAZIDE Repurposing	Small molecule	Approved	Strong	95	3 Trial pubs 3 RCT View evidence Published literature Clinical trial publication Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial (PloS one, 2025) Clinical trial publication Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial (Hepatology international, 2023) Clinical trial publication Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial (European heart journal, 2022) CT.gov search · Cochrane · PubMed	DGIdb	—
HYDROGEN PEROXIDE Repurposing	Small molecule	Approved	Strong	95	37 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMIPRAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
INDOMETHACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IRBESARTAN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
IRBESARTAN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISTRADEFYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVODOPA Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LIRAGLUTIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
LOSARTAN POTASSIUM Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
MAFENIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MARAVIROC Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MECAMYLAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MEFLOQUINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
MESALAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
METFORMIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MORPHINE SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NABILONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
NALIDIXIC ACID Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLMESARTAN MEDOXOMIL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ORLISTAT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
OXTRIPHYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PEGINTERFERON ALFA-2B Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PENTOXIFYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL Repurposing	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients (European journal of pharmacology, 2015) CT.gov search · Cochrane · PubMed	DGIdb	—
PHENYTOIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PLERIXAFOR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
REGADENOSON Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
REGADENOSON ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RIBAVIRIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
RIMONABANT Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SARALASIN ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SIMVASTATIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing	Small molecule	Approved	Strong	95	1 trials 1 Trial pubs View evidence Registry trials NCT07391267 — Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NOT_YET_RECRUITING) NA Published literature Clinical trial publication [Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy] (Terapevticheskii arkhiv, 2013) CT.gov search · Cochrane · PubMed	DGIdb	—
SPARSENTAN Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SULBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TELMISARTAN Repurposing	Small molecule	Approved	Strong	95	1 Meta-analysis 2 Trial pubs 2 RCT View evidence Published literature Meta-analysis Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis (Postgraduate medical journal, 2018) Clinical trial publication Effects of Orlistat or Telmisartan on the Serum Free Fatty Acids in Non-alcoholic Fatty Liver Disease Patients: An Open-Labeled Randomized Controlled Study (The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022) Clinical trial publication Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial (Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 2016) CT.gov search · Cochrane · PubMed	DGIdb	—
THEOPHYLLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
THEOPHYLLINE SODIUM GLYCINATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TROGLITAZONE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALSARTAN Repurposing	Small molecule	Approved	Strong	95	4 Trial pubs 4 RCT View evidence Published literature Clinical trial publication Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial (PloS one, 2025) Clinical trial publication Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial (Hepatology international, 2023) Clinical trial publication Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial (European heart journal, 2022) Clinical trial publication PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol (Archives of Iranian medicine, 2015) CT.gov search · Cochrane · PubMed	DGIdb	—
VIDARABINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ADEMETIONINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CENICRIVIROC	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ELAFIBRANOR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOMIDOCHOLIC ACID	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LANIFIBRANOR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LIRAGLUTIDE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LOSARTAN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
METRELEPTIN	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
OBETICHOLIC ACID	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SAROGLITAZAR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
VITAMIN E	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1364	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL178459	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL5314358	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
DENIFANSTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIOSMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFIMOSFERMIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFRUXIFERMIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROXYTYROSOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
OMEGA-3-ACID ETHYL ESTERS	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGOZAFERMIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIMONABANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SELONSERTIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SURVODUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
UBIDECARENONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VILDAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARAPLADIB Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
ALDAFERMIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BELAPECTIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BETAINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CILOFEXOR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
COTADUTIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
DIGOXIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ELOBIXIBAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
EMRICASAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
EXENATIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
EZETIMIBE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FENOFIBRATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FIRSOCOSTAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
GEMCABENE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOSABUTATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOSAPENT ETHYL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
K-877	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEVOCARNITINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LICOGLIFLOZIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MB07811	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIRICORILANT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MT-3995	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NAMODENOSON	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NIDUFEXOR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NIVOCASAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
OLESOXIME	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGBELFERMIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROFLUMILAST	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SELADELPAR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SITAGLIPTIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SOLITHROMYCIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TIRZEPATIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TROPIFEXOR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
URSODIOL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ASP-9831	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AVENCIGUAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERBERINE URSODEOXYCHOLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAGRILINTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CC-90001	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1200577	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201473	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201608	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1232863	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1236395	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL165	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1682	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2107951	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2364624	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL295124	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3822773	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL404271	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4074884	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297588	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297909	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL431701	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL843	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL995	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHIGLITAZAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHOLESTYRAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLESACOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CM-101	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COLESEVELAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CPD (S)-22	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOCONEXENT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFINOPEGDUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFOCIPEGTRUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEBUXOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORALUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GUANABENZ ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HPG-1860	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOTHYROXINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAZDUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MISOPROSTOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MITIPERSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NALMEFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NITAZOXANIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NORUCHOLIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGARGIMINASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMAFIBRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMVIDUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-06865571	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAPIROSIRAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RENCOFILSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAR425899	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILYMARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIMTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TERN-101	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE UNDECANOATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOFOGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VOLIXIBAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VONAFEXOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZALFERMIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BELNACASAN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL415893 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CLESACOSTAT Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
COMPOUND 21 [PMID: 23981033] Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
CP-640186 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
FIRSOCOSTAT Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ILACIRNON Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
OLUMACOSTAT GLASARETIL Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
PF-05175157 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
PRALNACASAN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TAK-220 Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TASOSARTAN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TOFA Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	—
VERMISTATIN Repurposing	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ALPRENOLOL Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
PROGLUMIDE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
SPIRONOLACTONE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
CHEMBL106	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL113	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200421	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1294	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1715	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109070	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL374478	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL539697	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL655	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CYSTEAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DEFERASIROX	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ECNOGLUTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESOMEPRAZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IDEBENONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONASEMNOGENE ABEPARVOVEC	Gene therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONTAMALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OTENABANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OTENABANT HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SELVIGALTIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOLIXIBAT POTASSIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALANINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CANAGLIFLOZIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GUSELKUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIFAXIMIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SEVOFLURANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TESAMORELIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
RESMETIROM	Small molecule	Approved	Strong	105	4 trials 7 Cochrane 9 Meta-analysis 9 Trial pubs 9 RCT View evidence Registry trials NCT07335601 — Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH (RECRUITING) PHASE2 NCT07680478 — Nutrition Intervention Combined With Resmetirom for MASH (NOT_YET_RECRUITING) PHASE4 NCT07249788 — Resmiterom Efficacy & Safety in Patients With MASH (RECRUITING) PHASE4 NCT07541469 — Rezdiffra Pregnancy and Lactation Registry (RECRUITING) Published literature Cochrane review The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026) Cochrane review Divergent effect of diabetes on fibrosis response to semaglutide and resmetirom in noncirrhotic MASH: A meta-analysis of randomized trials (Med (New York, N.Y.), 2026) Cochrane review Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH) (Diabetes, obesity & metabolism, 2026) Cochrane review Clinical Assessment of Common Medications for Nonalcoholic Fatty Liver Disease: A Systematic Review and Bayesian Network Meta-Analysis (Journal of evidence-based medicine, 2025) Cochrane review Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials (Journal of basic and clinical physiology and pharmacology, 2025) Meta-analysis Development of a cross-species model to predict clinical outcomes based on efficacy in mouse models of non-alcoholic fatty liver disease (Clinics and research in hepatology and gastroenterology, 2025) Meta-analysis Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction-associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta-analysis (Diabetes, obesity & metabolism, 2025) Meta-analysis A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis (Liver international : official journal of the International Association for the Study of the Liver, 2025) Systematic review Efficacy and safety of resmetirom for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis (European journal of gastroenterology & hepatology, 2025) Systematic review Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2024) Clinical trial publication Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis (Hepatology communications, 2026) Clinical trial publication Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial (Alimentary pharmacology & therapeutics, 2025) CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
ADEMETIONINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CENICRIVIROC	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
DAPAGLIFLOZIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ELAFIBRANOR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
EMPAGLIFLOZIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOMIDOCHOLIC ACID	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LANIFIBRANOR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LIRAGLUTIDE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
LOSARTAN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
METRELEPTIN	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
OBETICHOLIC ACID	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PENTOXIFYLLINE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
PIOGLITAZONE	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROSUVASTATIN	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SAROGLITAZAR	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
SEMAGLUTIDE	Biologic	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
VITAMIN E	Small molecule	Phase III	Moderate	85	—	Open Targets, ChEMBL	ChEMBL Open Targets
CHEMBL1364	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL178459	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHEMBL5314358	Small molecule	Phase III	Moderate	80	—	ChEMBL	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
DENIFANSTAT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DIOSMIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFIMOSFERMIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EFRUXIFERMIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ESTRADIOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
HYDROXYTYROSOL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METFORMIN	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
OMEGA-3-ACID ETHYL ESTERS	Small molecule	Phase III	Moderate	80	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGOZAFERMIN	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
RIMONABANT	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SELONSERTIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SURVODUTIDE	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
UBIDECARENONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VILDAGLIPTIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ALDAFERMIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BELAPECTIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
BETAINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
CILOFEXOR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
COTADUTIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
DIGOXIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ELOBIXIBAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
EMRICASAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
EXENATIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
EZETIMIBE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FENOFIBRATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
FIRSOCOSTAT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
GEMCABENE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOSABUTATE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOSAPENT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ICOSAPENT ETHYL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
INSULIN HUMAN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
K-877	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LEVOCARNITINE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
LICOGLIFLOZIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MB07811	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MIRICORILANT	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
MT-3995	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NAMODENOSON	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NIDUFEXOR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
NIVOCASAN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
OLESOXIME	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
PEGBELFERMIN	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROFLUMILAST	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ROSIGLITAZONE	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SELADELPAR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SITAGLIPTIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
SOLITHROMYCIN	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TIRZEPATIDE	Biologic	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
TROPIFEXOR	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
URSODIOL	Small molecule	Phase II	Moderate	60	—	Open Targets, ChEMBL	ChEMBL Open Targets
ASP-9831	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ATORVASTATIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AVENCIGUAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
BERBERINE URSODEOXYCHOLATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CAGRILINTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CC-90001	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHEMBL1200577	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201473	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1201608	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1232863	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1236395	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL165	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL1682	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2107951	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL2364624	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL295124	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL3822773	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL404271	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4074884	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297588	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL4297909	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL431701	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL843	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHEMBL995	Small molecule	Phase II	Emerging	60	—	ChEMBL	ChEMBL Open Targets
CHIGLITAZAR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CHOLESTYRAMINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CLESACOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CM-101	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
COLESEVELAM	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
CPD (S)-22	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
DOCONEXENT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFINOPEGDUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
EFOCIPEGTRUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FEBUXOSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
FORALUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
GUANABENZ ACETATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
HPG-1860	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LERONLIMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
LEVOTHYROXINE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MAZDUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MISOPROSTOL	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
MITIPERSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NALMEFENE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NITAZOXANIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
NORUCHOLIC ACID	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEGARGIMINASE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMAFIBRATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PEMVIDUTIDE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PF-06865571	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RAPIROSIRAN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
RENCOFILSTAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SAR425899	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SILYMARIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
SIMTUZUMAB	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TERN-101	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TESTOSTERONE UNDECANOATE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
TOFOGLIFLOZIN	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VOLIXIBAT	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
VONAFEXOR	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ZALFERMIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
PROGLUMIDE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
SPIRONOLACTONE	Small molecule	Phase I	Emerging	40	—	Open Targets, ChEMBL	ChEMBL Open Targets
ACETYLCYSTEINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
BICALUTAMIDE	Small molecule	Phase I	Emerging	35	No indexed hits View evidence CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
CHEMBL106	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL113	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1200421	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1294	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL1715	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL2109070	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL374478	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL539697	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CHEMBL655	Small molecule	Phase I	Emerging	35	—	ChEMBL	ChEMBL Open Targets
CYSTEAMINE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
DEFERASIROX	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ECNOGLUTIDE	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ESOMEPRAZOLE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
IDEBENONE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
MONTELUKAST	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONASEMNOGENE ABEPARVOVEC	Gene therapy	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ONTAMALIMAB	Biologic	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OTENABANT	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
OTENABANT HYDROCHLORIDE	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
SELVIGALTIN	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
VOLIXIBAT POTASSIUM	Small molecule	Phase I	Emerging	35	—	Open Targets	ChEMBL Open Targets
ALANINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
ASPIRIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
CANAGLIFLOZIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
GUSELKUMAB	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
HYDROXYCHLOROQUINE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
PROPOFOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
RIFAXIMIN	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
SEVOFLURANE	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TAURURSODIOL	Small molecule	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets
TESAMORELIN	Biologic	Preclinical	Emerging	15	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACETAZOLAMIDE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ADENOSINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
ALITRETINOIN Repurposing via CCR2	Small molecule	Approved	Strong	95	—	DGIdb	—
AMINOPHYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
AMPHETAMINE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANGIOTENSIN II Repurposing via AGTR1	Small molecule	Approved	Strong	95	2 Trial pubs 2 RCT View evidence Published literature Clinical trial publication Randomized placebo-controlled trial of losartan for pediatric NAFLD (Hepatology (Baltimore, Md.), 2022) Clinical trial publication A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis (PloS one, 2017) CT.gov search · Cochrane · PubMed	DGIdb	—
ANGIOTENSIN II ACETATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ASCORBIC ACID Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
ATORVASTATIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 Cochrane 1 Meta-analysis 13 Trial pubs 12 RCT View evidence Published literature Cochrane review Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (The Cochrane database of systematic reviews, 2013) Clinical trial publication Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial (PloS one, 2025) Clinical trial publication Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial (Hepatology international, 2023) Clinical trial publication Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial (European heart journal, 2022) Clinical trial publication Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role? (Current vascular pharmacology, 2021) Clinical trial publication CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients (Liver international : official journal of the International Association for the Study of the Liver, 2019) CT.gov search · Cochrane · PubMed	DGIdb	—
ATORVASTATIN CALCIUM TRIHYDRATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
AZILSARTAN KAMEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
AZILSARTAN MEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ACACA	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL Open Targets
CAFFEINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
CAFFEINE CITRATE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
CANDESARTAN CILEXETIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CANNABIDIOL Repurposing via CNR1	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPTOPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	2 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CARBACHOL Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CLOMIPRAMINE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CYCLOSPORINE Repurposing via AGTR1	Small molecule	Approved	Strong	95	8 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DEFIBROTIDE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
DEXAMETHASONE Repurposing via AGTR1	Small molecule	Approved	Strong	95	15 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
DIAZEPAM Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DICHLORPHENAMIDE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DIETHYLSTILBESTROL Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
DISULFIRAM Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 Trial pubs View evidence Published literature Clinical trial publication Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism (Nature communications, 2022) CT.gov search · Cochrane · PubMed	DGIdb	—
DRONABINOL Repurposing via CNR1	Small molecule	Approved	Strong	95	—	DGIdb	—
EPIRUBICIN Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
EPROSARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
EPROSARTAN MESYLATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ETHOXZOLAMIDE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
FLAVONE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
FLUMAZENIL Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
GENISTEIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 Cochrane 2 Meta-analysis 1 Trial pubs 1 RCT View evidence Published literature Cochrane review Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis (Frontiers in immunology, 2022) Meta-analysis Therapeutic potential of traditional Chinese medicine in the prevention and treatment of digestive inflammatory cancer transformation: Portulaca oleracea L. as a promising drug (Journal of ethnopharmacology, 2024) Systematic review Polyphenol Intervention Ameliorates Non-Alcoholic Fatty Liver Disease: An Updated Comprehensive Systematic Review (Nutrients, 2024) Clinical trial publication Genistein supplementation improves insulin resistance and inflammatory state in non-alcoholic fatty liver patients: A randomized, controlled trial (Clinical nutrition (Edinburgh, Scotland), 2018) CT.gov search · Cochrane · PubMed	DGIdb	—
GLATIRAMER Repurposing via CCR5	Small molecule	Approved	Strong	95	—	DGIdb	—
HYDROCHLOROTHIAZIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	3 Trial pubs 3 RCT View evidence Published literature Clinical trial publication Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial (PloS one, 2025) Clinical trial publication Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial (Hepatology international, 2023) Clinical trial publication Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial (European heart journal, 2022) CT.gov search · Cochrane · PubMed	DGIdb	—
HYDROGEN PEROXIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	37 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
IMIPRAMINE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDAPAMIDE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
INDOMETHACIN Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 pubs View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
INDOMETHACIN Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
IRBESARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
IRBESARTAN HYDROCHLORIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
ISOSORBIDE DINITRATE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ISTRADEFYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
LEVODOPA Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
LIRAGLUTIDE Repurposing via CNR1	Small molecule	Approved	Strong	95	—	DGIdb	—
LOSARTAN POTASSIUM Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
MAFENIDE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MARAVIROC Repurposing via CCR5	Small molecule	Approved	Strong	95	—	DGIdb	—
MECAMYLAMINE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MEFLOQUINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
MESALAMINE Repurposing via CASP1	Small molecule	Approved	Strong	95	—	DGIdb	—
METFORMIN HYDROCHLORIDE Repurposing via COXFA4L2	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
METHAZOLAMIDE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METHOXSALEN Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
METOPROLOL Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MIANSERIN Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
MORPHINE SULFATE Repurposing via CCR2	Small molecule	Approved	Strong	95	—	DGIdb	—
NABILONE Repurposing via CNR1	Small molecule	Approved	Strong	95	—	DGIdb	—
NALIDIXIC ACID Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NICOTINE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
NORFLOXACIN Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OFLOXACIN Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
OLMESARTAN MEDOXOMIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	—
ORLISTAT Repurposing via CNR1	Small molecule	Approved	Strong	95	—	DGIdb	—
OXTRIPHYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
PEGINTERFERON ALFA-2B Repurposing via CASP1	Small molecule	Approved	Strong	95	—	DGIdb	—
PENTOXIFYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
PERINDOPRIL Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 Trial pubs 1 RCT View evidence Published literature Clinical trial publication Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients (European journal of pharmacology, 2015) CT.gov search · Cochrane · PubMed	DGIdb	—
PHENYTOIN Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
PLERIXAFOR Repurposing via CCR2	Small molecule	Approved	Strong	95	—	DGIdb	—
PRAZOSIN Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
REGADENOSON Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
REGADENOSON ANHYDROUS Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
RIBAVIRIN Repurposing via CASP1	Small molecule	Approved	Strong	95	—	DGIdb	—
RIMONABANT Repurposing via CNR1	Small molecule	Approved	Strong	95	—	DGIdb	—
SARALASIN ACETATE Repurposing via AGTR1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
SIMVASTATIN Repurposing via CCR2	Small molecule	Approved	Strong	95	—	DGIdb	—
SIROLIMUS Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
SODIUM CHLORIDE Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 trials 1 Trial pubs View evidence Registry trials NCT07391267 — Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. (NOT_YET_RECRUITING) NA Published literature Clinical trial publication [Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy] (Terapevticheskii arkhiv, 2013) CT.gov search · Cochrane · PubMed	DGIdb	—
SPARSENTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
SULBACTAM Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TAZOBACTAM Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
TELMISARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	1 Meta-analysis 2 Trial pubs 2 RCT View evidence Published literature Meta-analysis Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis (Postgraduate medical journal, 2018) Clinical trial publication Effects of Orlistat or Telmisartan on the Serum Free Fatty Acids in Non-alcoholic Fatty Liver Disease Patients: An Open-Labeled Randomized Controlled Study (The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022) Clinical trial publication Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial (Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 2016) CT.gov search · Cochrane · PubMed	DGIdb	—
THEOPHYLLINE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	—
THEOPHYLLINE SODIUM GLYCINATE Repurposing via ADORA2A	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
TROGLITAZONE Repurposing via ACACA	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
VALSARTAN Repurposing via AGTR1	Small molecule	Approved	Strong	95	4 Trial pubs 4 RCT View evidence Published literature Clinical trial publication Effects of a polypill on circulating levels of resistin and visfatin in men with non-alcoholic fatty liver disease: A five-year clinical trial (PloS one, 2025) Clinical trial publication Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial (Hepatology international, 2023) Clinical trial publication Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial (European heart journal, 2022) Clinical trial publication PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol (Archives of Iranian medicine, 2015) CT.gov search · Cochrane · PubMed	DGIdb	—
VIDARABINE Repurposing via ADORA2B	Small molecule	Approved	Strong	95	—	DGIdb	—
DARAPLADIB Repurposing via ACACA	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
FENRETINIDE Repurposing via ACACA	Small molecule	Phase III	Moderate	70	—	ChEMBL	ChEMBL Open Targets
BELNACASAN Repurposing via CASP1	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CHEMBL:CHEMBL415893 Repurposing via CASP1	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
CLESACOSTAT Repurposing via ACACA	Small molecule	Phase II	Emerging	50	—	DGIdb	—
COMPOUND 21 [PMID: 23981033] Repurposing via ACACA	Small molecule	Phase II	Emerging	50	—	DGIdb	—
CP-640186 Repurposing via ACACA	Small molecule	Phase II	Emerging	50	—	DGIdb	—
FIRSOCOSTAT Repurposing via ACACA	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ILACIRNON Repurposing via CCR2	Small molecule	Phase II	Emerging	50	—	DGIdb	—
OLUMACOSTAT GLASARETIL Repurposing via ACACA	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
PF-05175157 Repurposing via ACACA	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
PRALNACASAN Repurposing via CASP1	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TAK-220 Repurposing via CCR5	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TASOSARTAN Repurposing via AGTR1	Small molecule	Phase II	Emerging	50	—	DGIdb	—
TOFA Repurposing via ACACA	Small molecule	Phase II	Emerging	50	—	DGIdb	—
VERMISTATIN Repurposing via CASP1	Small molecule	Phase II	Emerging	50	—	DGIdb	ChEMBL Open Targets
ALPRENOLOL Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
AMIFLOXACIN Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
BROLAMFETAMINE Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
CARZENIDE Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIFLOXACIN Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
DIMECAMINE Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ELLAGIC ACID Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ENISOPROST Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FENCAMFAMIN Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
FLEROXACIN Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
IDOXIFENE Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
LYSERGIDE Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
MERAFLOXACIN Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
TENAMFETAMINE Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets
ZIDAPAMIDE Repurposing via ACACA	Small molecule	Phase II	Emerging	45	—	ChEMBL	ChEMBL Open Targets

Natural Products

48 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Probiotics Natural product Meta-analysis Gut Microbiota and Liver Health: Meta-Analysis of Bifidobacterium-Conta… Meta-analysis Strategic interventions in clinical randomized trials for metabolic dys… Meta-analysis Meta-analysis of randomized controlled trials of the effects of synbiot…	Probiotic	Phase II	Emerging	16	8 trials 27 Meta-analysis 21 Trial pubs View evidence Registry trials NCT07534241 — Hepatoprotective Effects of Reishi Mushroom- (Ganoderma Lucidum) Among Metabolic Dysfunction-associated Fatty Liver Disease Patients (RECRUITING) NA NCT06537882 — Evaluate the Effect of Synbiotics on MAFLD (ACTIVE_NOT_RECRUITING) NA NCT07400367 — Impact of a Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (RECRUITING) NA NCT06491342 — Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease (COMPLETED) NA NCT07193927 — Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial (RECRUITING) PHASE2 NCT07025980 — Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease. (NOT_YET_RECRUITING) PHASE2 NCT06873165 — Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to Clinical Trials (RECRUITING) NA NCT04555434 — Effects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH (COMPLETED) PHASE1, PHASE2 Published literature Meta-analysis Gut Microbiota and Liver Health: Meta-Analysis of Bifidobacterium-Containing Probiotics in NAFLD Management (International journal of molecular sciences, 2025) Meta-analysis Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: a systematic review with meta-analysis and bibliometric analysis (BMC medicine, 2024) Meta-analysis Meta-analysis of randomized controlled trials of the effects of synbiotics, probiotics, or prebiotics in controlling glucose homeostasis in non-alcoholic fatty liver disease patients (Food & function, 2024) Meta-analysis Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials (BMC gastroenterology, 2024) Meta-analysis The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials (Journal of diabetes and its complications, 2024) CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	—
Glycine Natural product Ammonia in the crosshairs: microbial targets for metabolic dysfunction-… Metabolic dysfunction-associated steatohepatitis exacerbated by Clostri… GCSH promotes MASH progression by regulating cuproptosis through the gl…	Amino acid	Phase I	Emerging	13	1 trials 2 Trial pubs 2 RCT View evidence Registry trials NCT07285135 — Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease (NOT_YET_RECRUITING) NA CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
L-Citrulline Natural product	Amino acid	Phase I	Emerging	10	1 trials View evidence Registry trials NCT05778266 — Effect of L-citrulline and HIIT on Arterial Stiffness, Body Composition, and Lipid Profile in Adolescents with Steatosis Associated with Metabolic Dysfunction (MASLD) (COMPLETED) NA CT.gov search · Cochrane · PubMed	ClinicalTrials.gov	PubChem
Cgs-15943 Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Neca Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Zm-241385 Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
8-PHENYL Theophylline Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Eprosartan Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Irbesartan Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Valsartan Natural product Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated Wi… Alterations of valsartan pharmacokinetics in a rodent model of metaboli…	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Tasosartan Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Losartan Potassium Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Rac-Ibipinabant Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Ibipinabant Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Rimonabant Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Win-552122 Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Anandamide Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
Nabilone Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
N-Propylpalmitamide Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
N-Methylpalmitamide Natural product	Food compound	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	ChEMBL	ChEMBL PubChem ChEMBL
N-Isopropylpalmitamide Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(Z)-octadec-11-enoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(9Z,12Z)-octadeca-9,12-dienoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
undecanoic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
caprylic acid [(E,1R)-1-(1-hydroxy-1-methyl-ethyl)-6-(2-ketochromen-7-yl)oxy-4-methyl-hex-4-enyl] ester Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
3-methylbutyric acid [(2S,3R,4R)-2-(4-hydroxy-3-methoxy-phenyl)-4-vanillyl-tetrahydrofuran-3-yl]methyl ester Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Talabostat Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Vildagliptin Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Raloxifene Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Estradiol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Estrone Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Diethylstilbestrol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Alfatradiol Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Raloxifene Core Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Genistein Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Mifepristone Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Motesanib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Pazopanib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Staurosporine Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Nintedanib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Lestaurtinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
A-443654 Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Fedratinib Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
Doramapimod Natural product	Food compound	Preclinical	Emerging	0	—	ChEMBL	ChEMBL PubChem ChEMBL
(3S,4R,5R)-2-methyloltetrahydropyran-2,3,4,5-tetrol Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
(3R,4S,5S,6R)-6-methyloltetrahydropyran-2,3,4,5-tetrol Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
(2S,3R,4S,5R,6R)-3,4,5,6-tetrahydroxytetrahydropyran-2-carboxylic acid Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem
zinc bis(1-oxidopyridin-1-ium-2-thiolate) Natural product	Food compound	Preclinical	Emerging	0	—	ClinicalTrials.gov	PubChem

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

NAFLD / MASH (Metabolic-Associated Steatohepatitis)

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network